Payment overview · 2025
General Payments
$236.13
13 reported records · 10 companies
Healthcare provider profile · identity verified
Humza Bin Waheed, M.D.
Allopathic & Osteopathic Physicians|General Practice · MEXICO, MO · NPI 1689938524
Verified facts
What the public records show
CMS Open Payments records show Humza Bin Waheed, M.D. received $236.13 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.54 | 17.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.31 | 14.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.99 | 12.7% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.09 | 10.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.54 | 10.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.77 | 8.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.46 | 7.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.72 | 7.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.17 | 6.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.54 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.13 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.99 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 100 |
| Lisinopril | Lisinopril | 342 | 78 |
| Tramadol Hcl | Tramadol Hcl | 320 | 63 |
| Omeprazole | Omeprazole | 304 | 57 |
| Gabapentin | Gabapentin | 282 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 262 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 39 |
| Metformin Hcl | Metformin Hcl | 170 | 37 |
| Potassium Chloride | Potassium Chloride | 169 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 30 |
| Furosemide | Furosemide | 135 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 32 |
| Jardiance | Empagliflozin | 123 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 36 |
| Simvastatin | Simvastatin | 113 | 24 |
| Meloxicam | Meloxicam | 108 | 39 |
| Metformin Hcl Er | Metformin Hcl | 96 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 20 |
| Propranolol Hcl | Propranolol Hcl | 75 | suppressed |
| Topiramate | Topiramate | 75 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 74 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 68 | 26 |
| Famotidine | Famotidine | 60 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 59 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | suppressed |
| Glipizide | Glipizide | 51 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 51 | 14 |
| Prednisone | Prednisone | 49 | 32 |
| Ibuprofen | Ibuprofen | 48 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 36 |
| Celecoxib | Celecoxib | 45 | suppressed |
| Clonazepam | Clonazepam | 45 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 14 |
| Buspirone Hcl | Buspirone Hcl | 40 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | 12 |
| Clozapine | Clozapine | 36 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Spravato | Esketamine Hcl | 35 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 12 |
| Losartan Potassium | Losartan Potassium | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 23 |
| Linzess | Linaclotide | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Carvedilol | Carvedilol | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Fluconazole | Fluconazole | 24 | 18 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Xeljanz | Tofacitinib Citrate | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Voquezna | Vonoprazan Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.13 · 13 records | Exact Sciences Corporation | AUSTEDO XR, COBENFY, Cologuard Collection Kit, FANAPT, INGREZZA, Korlym, NINLARO, REXULTI, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error